Spectrum Planning & Advisory Services Inc. Has $924,000 Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Spectrum Planning & Advisory Services Inc. decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,359 shares of the biopharmaceutical company’s stock after selling 201 shares during the quarter. Alnylam Pharmaceuticals accounts for approximately 0.9% of Spectrum Planning & Advisory Services Inc.’s investment portfolio, making the stock its 21st largest position. Spectrum Planning & Advisory Services Inc.’s holdings in Alnylam Pharmaceuticals were worth $924,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in ALNY. Pathstone Holdings LLC increased its position in Alnylam Pharmaceuticals by 11.2% during the 3rd quarter. Pathstone Holdings LLC now owns 6,249 shares of the biopharmaceutical company’s stock worth $1,719,000 after purchasing an additional 629 shares in the last quarter. TrinityPoint Wealth LLC acquired a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $200,000. Swiss National Bank grew its stake in shares of Alnylam Pharmaceuticals by 0.3% during the third quarter. Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock worth $103,246,000 after buying an additional 1,000 shares during the last quarter. Mutual of America Capital Management LLC increased its holdings in shares of Alnylam Pharmaceuticals by 26.7% during the third quarter. Mutual of America Capital Management LLC now owns 1,924 shares of the biopharmaceutical company’s stock worth $529,000 after buying an additional 405 shares in the last quarter. Finally, Natixis Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $2,751,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 1.4 %

Alnylam Pharmaceuticals stock opened at $232.27 on Tuesday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The business’s fifty day moving average is $274.53 and its 200 day moving average is $236.10. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The company’s revenue was down 33.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.15 EPS. Equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday. Raymond James upped their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research note on Friday, November 1st. Citigroup increased their price target on Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Finally, Wells Fargo & Company increased their target price on shares of Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the company an “equal weight” rating in a research report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.